IonQ Piles on Milestones — Dublin Hardware Deployment and Primate Research — While the Stock Continues to Slump

IonQ unveils 256-qubit Dublin system and quantum primate conflict study with Jane Goodall Institute, but stock drops 35% despite 755% revenue growth.

IonQ is expanding the reach of its quantum computing platform into two vastly different arenas: a commercial 256-qubit system destined for Dublin and a research project examining the roots of animal conflict alongside the Jane Goodall Institute. Yet neither announcement has reversed the downward pressure on the company’s shares, which have shed more than a third of their value in the past month despite record revenue growth.

Horizon Quantum Holdings, a company focused on building hardware-independent quantum applications, will integrate an IonQ ion-trap system at its European headquarters in Dublin. The 256-qubit machine is part of Ireland’s national semiconductor strategy and is designed to enable real-time compiler execution, allowing researchers to optimize hybrid quantum-classical algorithms at commercial scale. IonQ has already hit key tape-out milestones for chip-based 256-qubit systems and is opening pre-orders, with a fully commercial version targeted for the fourth quarter of 2026.

On a completely different front, IonQ’s hardware is also being deployed to explore why some primate species wage violent conflicts while others coexist peacefully. The Jane Goodall Institute USA and FormationQ announced a two-year research program, dubbed “Ecology of War and Peace,” that will use IonQ’s ion-trap platform to analyze group behavior in chimpanzees and bonobos. The project connects with the University of Minnesota’s B3GET agent-based simulation model and marks what the partners say is the first known application of quantum computing in behavioral ecology. For IonQ, the partnership serves as a visible demonstration that its systems can handle noisy, real-world datasets beyond traditional finance and optimization.

These operational wins, however, stand in stark contrast to the stock’s trajectory. IonQ closed Tuesday at €34.40, a drop of nearly 35% over the past 30 days and roughly 13% in the last week alone. The shares are now off more than 53% from the 52-week high of €73.10 reached last October, though they still trade about 52% above the year’s low of €22.60 struck in late March.

The selloff has occurred even as the company reported first-quarter 2026 revenue of $64.7 million, a 755% surge from a year earlier. Management subsequently raised its full-year 2026 revenue forecast to a range of $260 million to $270 million. The market cap currently stands at roughly €14 billion, and the stock’s 30-day annualized volatility runs at 84%, underscoring the nervousness surrounding the name.

Technical indicators suggest the shares may be oversold. The 14-day relative strength index sits at 30.1, hovering near the threshold often viewed as a reversal zone. The stock also trades about 28% below its 50-day moving average of €48.09 and roughly 18% below the 200-day average of €41.77, widening the gap from key support levels.

IonQ continues to prioritize growth and research spending, keeping it in the red for now. The Dublin deployment and the primate behavior study each demonstrate expanding use cases, but neither carries an immediate financial payoff — the Goodall project runs for two years with initial results expected no earlier than 2026. Meanwhile, broader market forces appear to be weighing on the equity more heavily than any single corporate development, leaving investors to weigh the gap between operational momentum and a stock that keeps sliding.